Partial Epilepsy Clinical Trial
Official title:
Improving Lesion Detection in Children With MRI-negative Partial Epilepsy Using Diffusion Tensor Imaging
Verified date | September 2013 |
Source | The Hospital for Sick Children |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Observational |
Focal cortical dysplasia is one of the most common lesions responsible for medically refractory epilepsy in the pediatric population. In patients with medically intractable epilepsy, surgery is the only treatment that will lead to seizure freedom. The outcome of epilepsy surgery is worse in patients when there is no lesion identified on routine structural MRI, also known as MRI-negative partial epilepsy. Diffusion tensor imaging (DTI), a novel MRI technique, can be used to evaluate the integrity of the microstructure of the white matter, even when the white matter appears normal on routine MRI.
Status | Completed |
Enrollment | 64 |
Est. completion date | May 2012 |
Est. primary completion date | May 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 6 Years to 18 Years |
Eligibility |
Inclusion Criteria: MRI negative partial epilepsy group: - Patients diagnosed with partial epilepsy according to the International League Against Epilepsy (ILAE) standard [53] - MRI study reported as normal - Age ranging from 6-18 years (DTI indices alter with myelination and the changes are most marked from birth to 4 years of age) MRI-visible FCD group: - Patients diagnosed with partial epilepsy according to the ILAE standard [53] - Visual assessment of MRI demonstrates one or more features of FCD - Cortical thickening - Alteration in sulci and gyri pattern, including deep sulci - Blurring of gray-white matter transition - T2 signal prolongation of the cortex and subcortical white matter - High T1 signal in the cortex - Age ranging from 6-18 years (DTI indices alter with myelination and the changes are most marked from birth to 4 years of age) Normal controls: - Subjects with no history of neurological diseases - Age ranging from 6-18 years (most children under the age of 6 years are unable to tolerate the MR examination without general anesthesia or sedation). - No requirement of general anesthesia or sedation Exclusion Criteria: - Subjects with contraindications for MR imaging (i.e. retained foreign bodies, implants) - Subjects with claustrophobia - Controls with a prior history of traumatic brain injury, neurological disorder, cerebral palsy, developmental delay or learning disability - Controls who require general anesthesia or sedation |
Observational Model: Cohort, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Canada | The Hospital for Sick Children | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
The Hospital for Sick Children |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identify DTI changes in the white matter of children with MRI-negative partial epilepsy and MRI-visible FCD using voxel-by-voxel analysis of FA and MD maps compared to normal controls. | 1 timepoint; immediately after MRI/DTI | No | |
Secondary | Determine if the lobar location of abnormal FA and MD correlate with the lobar location of MEG defined epileptogenic zone in MRI-negative partial epilepsy and MRI-visible FCD. | 1 timepoint; immediately after MRI/DTI | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00982787 -
Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy
|
Phase 2 | |
Completed |
NCT00898560 -
Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
|
Phase 1 | |
Recruiting |
NCT01735032 -
Multimodal Imaging in Pre-surgical Evaluation of Epilepsy
|
N/A | |
Completed |
NCT01090934 -
Localizing the Epileptogenic Zone With High Resolution Electroencephalography
|
N/A | |
Terminated |
NCT00391534 -
EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy
|
Phase 3 | |
Terminated |
NCT01496612 -
Buspirone Therapy for Localized Epilepsy
|
Phase 2 | |
Completed |
NCT00900237 -
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
|
Phase 1 | |
Recruiting |
NCT04903314 -
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
|
Phase 1 | |
Completed |
NCT01373190 -
Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy
|
N/A | |
Recruiting |
NCT03478852 -
Investigating Epilepsy: Screening and Evaluation
|
||
Recruiting |
NCT01273129 -
Surgery as a Treatment for Medically Intractable Epilepsy
|
||
Completed |
NCT00001666 -
Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy
|
N/A | |
Completed |
NCT00001932 -
Serotonin Receptors in Seizure Disorders
|
N/A | |
Completed |
NCT00908349 -
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
|
Phase 3 | |
Completed |
NCT02076698 -
Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy
|
Phase 3 | |
Completed |
NCT00706160 -
Language Mapping in Patients With Epilepsy
|
||
Completed |
NCT01397968 -
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
|
Phase 2 | |
Completed |
NCT01866111 -
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
|
Phase 2 | |
Completed |
NCT00957047 -
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
|
Phase 3 | |
Terminated |
NCT01281956 -
PRX-00023 Therapy in Localization-Related Epilepsy
|
Phase 2 |